ClinicalTrials.gg
RecruitingNCT07278973HD-OLDERUpdated Feb 23, 2026

Hemodiafiltration Versus Hemodialysis in Older People

An interventional study of High-flux hemodialysis and Hemodiafiltration in Hemodialysis, Hemodiafiltration and Fatigue Symptom, sponsored by AUB Santé. Recruiting at 4 sites in France. Open to participants aged 85 Years and older. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by AUB Santé · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
85 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 105 studies in Fatigue with a site in France — 34 open to participants now, 37 under way, 4 of them phase 3. Fatigue · France.

Planned enrollment
39th of 73
62 · median 70
Started
2026
with 7 others
No phase
61 of 105
23 open now
Primary completion
2026-12
later than 20 of 36 live
Registered
96th of 105
by date

Among the 105 studies in Fatigue with a site in France, this one is the 39th largest by planned enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2026, is one of 61 with no phase, reaches primary completion later than 20 of the 36 other live ones, and was the 96th registered.

Fatigue

2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.

Browse Fatigue studies →

Open to participants now

34 of the 105 studies in Fatigue with a site in France are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 242 Fatigue studies recruiting now, 113 (47%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.

This study: 85 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Fatigue with a site in France, or all of them as a file.
02

Study summary

This study will compare the impact of two hemodialysis techniques on fatigue and post-dialysis recovery time in patients aged 85 years and older. These two techniques are high-flux hemodialysis (HD) and hemodiafiltration (HDF).

Patients will receive the treatment over two periods: if period 1 is HD then period 2 will be HDF. Every patient will be his/her own control, this is why it is called cross-over. Each period will last three months. Between the two periods, patients will receive a traditional low-flux hemodialysis.

These two techniques are widely used worldwide and their side-effects are well-known and do not put the patients at risk. HDF has been shown to improve survival in patients with a mean age of 58 years. But a previous study from the investigators' group showed that HDF causes a prolonged recovery time in older patients. This randomized trial aims to elucidate this question.

Read the detailed description

Study purpose: To determine the best modality of hemodialysis in older patients > 84 years

Study Design: Randomized, multicenter, crossover, pragmatic clinical trial.

Eligible participants will be randomized in a 1:1 ratio for HDF or high-flux hemodialysis using a centralized, web-based randomization module integrated into the DATACAPT electronic case report form (eCRF). Allocation concealment will be ensured because the treatment assignment will only be generated after the patient has been enrolled and all eligibility criteria have been confirmed within the eCRF system.

Investigators and study personnel will not have access to the allocation sequence or block sizes prior to randomization.

Patients will be randomized to two sequences, each one of a 3-month period. Sequence 1 includes 3 months of hemodiafiltration (Period 1) then 3 months of high-flux hemodialysis (Period 2). Sequence 2 includes 3 months of high-flux hemodialysis (Period 1) then 3 months of hemodiafiltration (Period 2).

Washout period: Two weeks of low-flux hemodialysis at the beginning of the study and between the two periods of each sequence.

Blinding: the participant, investigators and outcome assessors are not blinded the intervention.

Primary objective: To compare the dialysis recovery time in older patients treated with hemodiafiltration versus conventional high-flux hemodialysis

Secondary objectives

  1. To compare the general fatigue between the two hemodialysis modalities
  2. To compare symptomatic hypotension and intradialytic clotting events
  3. To compare quality of life
  4. To compare dialysis adequacy
  5. To compare safety and adverse events

Eligibility criteria: described under the section "Eligibility".

Duration of study for each participant: 7 months (including 2 initial weeks of washout and 2 weeks of washout between period 1 and period 2) Total duration of study: 8-10 months

Data collection at screening/randomization

  • Eligibility criteria: clearly stated and documented in the eCRF.
  • Demographics: age, sex.
  • Comorbidities and medical history: diabetes, smoking, hypertension, hyperlipidemia, cause and date of kidney failure (dialysis vintage), previous cardiovascular disease, atrial fibrillation, Charlson score for comorbidity.
  • Vital signs: height and weight (dry weight). Pre-dialysis and post-dialysis systolic and diastolic blood pressure and heart rate in a sitting position will be recorded.
  • Dialysis prescription: Vascular access (arteriovenous fistula or graft, central venous catheter); number of dialysis hours per week; dialysis session time (morning, afternoon, evening); blood flow, dialysate flow, dialysate temperature, filter membranes (surface), dialysate potassium, sodium, calcium content and type (acetate, HCL or citrate), anticoagulation type and dose (heparin or LMWH) will be collected. Use of UF control (or profile) or Na control (or profile).
  • Laboratory pre-dialysis: urea, creatinine, serum phosphate, calcium, albumin, potassium, sodium, bicarbonate, hemoglobin, PTH, alkaline phosphatase, ferritin, transferrin saturation, uric acid, Kt/V (method of Kt/V assessment) to be recorded.
  • Laboratory post-dialysis: urea, creatinine.
  • Clinical variables: Urine volume will be assessed by collecting the 24 hour-urine and residual kidney function will be measured.
  • Medications: antihypertensive therapy: number of drugs, diuretics, renin angiotensin aldosterone system inhibitors (RAASi), CCBs, beta-blockers, alpha-blockers; antidepressants and anxiolytics. Statin, medications for diabetes, oral anticoagulant, ESA, Iron, drugs for hyperkalemia, phosphate binders, vitamin D, cinacalcet.
  • Dialysis recovery time (DRT) will be collected for three consecutive sessions and will be assessed by asking "How long did it take you to recover from your last dialysis session?" or in French "Combien de temps vous a-t-il fallu pour récupérer de votre dernière séance d'hémodialyse?". This question will be asked by nurses to each patient at each session for three consecutive sessions at the beginning, middle and end of each period of the trial. Answers will be recorded in minutes or hours.
  • Fatigue score will be assessed by using the French SONG-fatigue validated scale. The SONG-HD fatigue scale includes three questions: in the last week, "did you feel tired?", "did you lack energy?", "did fatigue limit your usual activities?". The response to these questions follows a 4-Likert scale: 0= not at all, 1=a little, 2=quite a bit, 3=severely. The total score of fatigue is defined as the sum of the three scores (0 to 9).
  • Stand-to-sit (STS 30) test: it is used to evaluate muscle performance and it is validated in patients on hemodialysis. It is assessed by asking the patient at the end of the session for three consecutive sessions to stand and sit on the chair as quickly as possible. The number of stand-to-sit over 30 seconds will be recorded.
  • Health-related quality of life will be assessed using the SF-12 quality of life score.

Data collection at follow-up

-Laboratory measurements The investigators will collect at one month, two months and three months of Period 1 and Period 2 the routine laboratory tests: serum urea, creatinine, phosphate, calcium, albumin, potassium, sodium, bicarbonate, hemoglobin, PTH, alkaline phosphatase, ferritin, transferrin saturation.

At the end of each period, residual kidney function will be collected.

  • Clinical follow-up: The number of symptomatic intradialytic hypotension episodes and of intradialytic clotting events will be documented in the patient's chart at each session and the total number will be collected at the end of each period of treatment. Pre- and post-dialysis systolic and diastolic blood pressure will be collected at the end of each period of the trial by computing the average of the last three sessions.
  • Number of hospital admissions and deaths, within each period, will be collected.
  • Dialysis parameters will be collected at one month, two months and three months of each period of the trial: blood flow, dialysate flow, dialysate temperature, ultrafiltration rate (mL/Kg/h), Kt/V, convective volume (for HDF), use of UF control (or profile) or Na control (or profile), dialysis session duration and time (morning, afternoon, evening).
  • Medications' follow-up: Any change in baseline medications to be collected every month: antihypertensive therapy, ESA, Iron, drugs for hyperkalemia, phosphate binders, vitamin D, cinacalcet.
  • Questionnaires DRT question, SONG-Fatigue questionnaire, STS-30 will be administered and recorded at 6 weeks and the end of Period 1 and Period 2. SF-12 Health Survey will be administered and recorded at the end of Period 1 and Period 2.

Primary and Secondary Endpoints: defined under the section "Outcome measures".

Planned number of participants: 62 patients

Statistical analysis Analyses will be performed on an intention-to-treat basis. Baseline characteristics will be compared using the independent t-test or Mann-Whitney U test for continuous variables and Chi-Square test for categorical variables. Linear mixed models will be used to compare the outcomes.

Ethics: The study will be conducted according to the principles of the Declaration of Helsinki 1975.

03

Conditions studied

  • Hemodialysis
  • Hemodiafiltration
  • Fatigue Symptom
  • Quality of Life of Patients
  • Older People

Browse trials for

Keywords

  • Hemodialysis
  • Hemodiafiltration
  • Older people
  • Fatigue
  • Patient reported outcome
  • Dialysis recovery time
04

Who can participate

Ages eligible
85 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated
  • Age >84 years
  • Diagnosed with kidney failure
  • On maintenance hemodialysis >3months
  • Willing to have a dialysis session of 3.5 to 4-hour duration, three times a week
  • Has a reliable vascular access
  • Is covered by the health insurance

Exclusion criteria

Exclusion Criteria:

  • Patients with cognitive impairment (assessed with a mini-test if needed)
  • Hospitalized at inclusion
  • Have difficulties with French speaking
  • Terminally ill with \<3 months
  • With active cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Sequence 1: HD HDF

    The patient will receive three months of HD followed by three months of HDF

    Other: High-flux hemodialysis · Other: Hemodiafiltration

  • Experimental
    Sequence 2: HDF HD

    The patient will receive three months of HDF followed by three months of HD

    Other: High-flux hemodialysis · Other: Hemodiafiltration

Interventions

  • OtherHigh-flux hemodialysis

    High-flux hemodialysis removes small and middle molecular solutes through the mechanism of diffusion.

  • OtherHemodiafiltration

    Hemodiafiltration removes solutes using convection which allows for more epuration of middle molecular solutes.

06

What researchers measure

Primary outcomes

  1. Change in dialysis recovery time

    Time in minutes that the patient needs after dialysis to recover energy

    Time frame: Three months

Secondary outcomes

  1. Change in fatigue score

    Fatigue will be assessed using the Standardized Outcomes in Nephrology (SONG) fatigue scale: from 0 to 9, higher meaning worse outcomes.

    Time frame: Three months

  2. Change in STS-30

    The number of stand-to-sit over 30 seconds will be recorded. The higher the better outcome.

    Time frame: Three months

  3. Change in SF-12 scores

    Quality of life scale (12 items), from 0 to 100, the higher the better outcome.

    Time frame: Three months

  4. Number of episodes of of symptomatic hypotension

    Drop in blood pressure with symptoms

    Time frame: Three months

  5. Number of intradialytic clotting events

    Time frame: Three months

  6. Change in hemoglobin level

    Time frame: Three months

  7. Change in serum albumin

    Time frame: Three months

  8. Change in serum potassium level

    Time frame: Three months

  9. Change in serum phosphate

    Time frame: Three months

  10. Change in Kt/V

    Dialysis adequacy

    Time frame: Three months

  11. Hospitalisation

    Whether the patient was admitted to hospital during the study period

    Time frame: From the start to the end of period 1 (HD) and from the start to the end of period 2 (HDF)

  12. Death

    Time frame: From the start to the end of period 1 (HD) and from the start to the end of period 2 (HDF)

07

Study locations

4 of 4 sites recruiting
  • AUB Santé
    Bretagne, France
    Recruiting
    • Thibault DOLLEY-HITZE, M.D. · Contactthibault.dolley-hitze@aub-sante.fr · +33299200140
    • Simon DUQUENNOY, M.D. · Contactsimon.duquennoy@aub-sante.fr
    • Thibault DOLLEY-HITZE, M.D. · Principal investigator
    • Eric LARUELLE, M.D. · Sub investigator
    • Morgane GOSSELIN, M.D. · Sub investigator
    • Bruno LEGENDRE, M.D. · Sub investigator
  • AIDER
    Grabels, 34790, France
    Recruiting
  • ECHO
    Le Mans, France
    Recruiting
    • Guillaume SERET, M.D. · Contactgseret@echo-sante.com · +33243432474
    • Frédéric LAVAINNE, M.D. · Contact
    • Guillaume SERET, M.D. · Principal investigator
    • Frédéric LAVAINNE, M.D. · Sub investigator
    • Lurlings GENDROT, M.D. · Sub investigator
    • Wael AL HAGGAN, M.D. · Sub investigator
  • Aura Paris
    Paris, France
    Recruiting
    • Pablo URENA, M.D. · Contactpablo.urena@auraparis.org · +33149189393
    • Rime OSSMANE, M.D. · Contact
    • Pablo URENA, M.D. · Principal investigator
    • Rime OSSMANE, M.D. · Sub investigator
    • Minh Hoang TRAN, M.D. · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.

Of 937 non-industry interventional studies with no phase under Fatigue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 10 months is below that.

Counting every sponsor, half of 990 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Dec 12, 2025
StartEst.
Feb 19, 2026
Primary completionEst.
Dec 19, 2026
CompletionEst.
Dec 19, 2026
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07278973
Lead sponsor
AUB Santé
Responsible party
Mabel Aoun (Nephrologist, AUB Santé) — Principal investigator
First posted
Dec 12, 2025
Start date
Feb 19, 2026 (estimated)
Primary completion
Dec 19, 2026 (estimated)
Completion
Dec 19, 2026 (estimated)
Last update
Feb 23, 2026

Study contacts

Mabel AOUN, M.D., M.P.H.
Contact
aounmabel@yahoo.fr
+33174743551
Sibylle Gourvil
Contact
sibylle.gourvil@aub-sante.fr
02.90.22.64.05
Mabel Aoun, M.D., M.P.H.
study chair · AUB SANTE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion